Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis.

TLR agonism cutaneous leishmaniasis immunotherapy therapeutic vaccination

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
17 Oct 2024
Historique:
received: 24 09 2024
revised: 10 10 2024
accepted: 15 10 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 26 10 2024
Statut: epublish

Résumé

Cutaneous leishmaniasis (CL), caused by protozoan parasites of the

Identifiants

DOI: 10.3390/vaccines12101179 PMID: 39460345
pubmed: 39460345
pii: vaccines12101179
doi: 10.3390/vaccines12101179
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Andrea Lafleur (A)

Doctoral Training Centre, University of Oxford, Oxford OX1 3NP, UK.
ORCID: 0000-0002-4541-2434

Stephane Daffis (S)

Drugs for Neglected Diseases initiative (DNDi), 1202 Geneva, Switzerland.
ORCID: 0000-0003-0403-3670

Charles Mowbray (C)

Drugs for Neglected Diseases initiative (DNDi), 1202 Geneva, Switzerland.
ORCID: 0000-0003-3538-8116

Byron Arana (B)

Drugs for Neglected Diseases initiative (DNDi), 1202 Geneva, Switzerland.

Classifications MeSH